KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent ...
Fierce Biotech19h
George Church spinout GRObio explores strategic alternatives 6 months after $60M series B
Synthetic biology specialist GRO Biosciences is exploring strategic alternatives about six months after raising a series B ...
EurekAlert!1d
IL2RG gene therapy for X-SCID
X-linked severe combined immunodeficiency disease (X-SCID) is a rare genetic disorder characterized by profound defects in ...
Cambridge Independent1d
$31m seed round success fires up TRIMTECH Therapeutics’ mission
TRIMTECH Therapeutics’s incredible $31million seed funding haul will be deployed to develop treatments for severe ...
Mirage News20h
IL2RG Gene Therapy Targets X-SCID
X-linked severe combined immunodeficiency disease (X-SCID) is a rare genetic disorder characterized by profound defects in T-cell, B-cell, and natural ...
GEN - Genetic Engineering and Biotechnology News1d
Holistic Approach to Improving Hard-to-Express Protein Yields
The team was able to reach protein yields at the pool stage that couldn’t be achieved previously with a random integration approach.
eLife2d
Exploring the repository of de novo-designed bifunctional antimicrobial peptides through deep learning
Peptides designed by artificial intelligence restrict both drug-resistant bacteria and rapidly evolving viruses.
BioPharma Dive4d
SynWeave™: Revolutionizing biopharma manufacturing by improving titer, timelines and manufacturability
Biopharma companies require optimal clone yields to ensure maximum concentration and effectiveness of these therapeutic ...
The Scientist2d
Peto’s Paradox: How Gigantic Species Evolved to Beat Cancer
Scientists dive into the genomes of whales, elephants, and other animal giants looking for new weapons in the fight against ...